Literature DB >> 36197465

Effects of vitamin E in preventing taxane‑induced peripheral neuropathy.

Shima Heidari1, Mona Kargar2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 36197465     DOI: 10.1007/s00280-022-04475-7

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.288


× No keyword cloud information.
  5 in total

1.  Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update.

Authors:  Charles L Loprinzi; Christina Lacchetti; Jonathan Bleeker; Guido Cavaletti; Cynthia Chauhan; Daniel L Hertz; Mark R Kelley; Antoinette Lavino; Maryam B Lustberg; Judith A Paice; Bryan P Schneider; Ellen M Lavoie Smith; Mary Lou Smith; Thomas J Smith; Nina Wagner-Johnston; Dawn L Hershman
Journal:  J Clin Oncol       Date:  2020-07-14       Impact factor: 44.544

2.  Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up.

Authors:  B Jordan; A Margulies; F Cardoso; G Cavaletti; H S Haugnes; P Jahn; E Le Rhun; M Preusser; F Scotté; M J B Taphoorn; K Jordan
Journal:  Ann Oncol       Date:  2020-07-30       Impact factor: 32.976

3.  The use of vitamin E in preventing taxane-induced peripheral neuropathy.

Authors:  Muhammad Ali Heiba; Soheir Sayed Ismail; Mohamed Sabry; Walid Abd Elmoniem Bayoumy; Khaled Abdel-Aziz Kamal
Journal:  Cancer Chemother Pharmacol       Date:  2021-09-01       Impact factor: 3.333

4.  The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors.

Authors:  Hannah C Timmins; Tiffany Li; David Goldstein; Terry Trinh; David Mizrahi; Michelle Harrison; Lisa G Horvath; Michael Friedlander; Matthew C Kiernan; Susanna B Park
Journal:  J Cancer Surviv       Date:  2021-02-27       Impact factor: 4.442

Review 5.  Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy.

Authors:  Hana Starobova; Irina Vetter
Journal:  Front Mol Neurosci       Date:  2017-05-31       Impact factor: 5.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.